ArticleCancer gene therapy2024

UGT1A7 altered HER2-positive breast cancer response to trastuzumab by affecting epithelial-to-mesenchymal transition: A potential biomarker to identify patients resistant to trastuzumab treatment.

Cong Wang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.